Zhang Yaowen, Wang Huitao, Huang Xiao, Zhang Qiang, Ren Runchuan, Sun Ronggang, Zheng Zhiyong, Dong Shangwen, Zheng Anping
Department of Radiation Oncology, Anyang Cancer Hospital, Anyang, Henan, China.
Department of Cardiothoracic Surgery, Tianjin Medical University General Hospital, Tianjin, China.
Med Dosim. 2019;44(2):167-172. doi: 10.1016/j.meddos.2018.05.001. Epub 2018 Jun 24.
The new TomoDirect (TD) modality offers a nonrotational option with discrete beam angles. We aim to compare dosimetric parameters of TD, helical tomotherapy (HT), volumetric-modulated arc therapy (VMAT), and fixed-field intensity-modulated radiotherapy (ff-IMRT) for upper thoracic esophageal carcinoma (EC).
Twenty patients with cT2-4N0-1M0 upper thoracic esophageal squamous cell carcinoma (ESCC) were enrolled. Four plans were generated using the same dose objectives for each patient: TD, HT, VMAT with a single arc, and ff-IMRT with 5 fields (5F). The prescribed doses were used to deliver 50.4 Gy/28F to the planning target volume (PTV50.4) and then provided a 9 Gy/5F boost to PTV59.4. Dose-volume histogram (DVH) statistics, dose uniformity, and dose homogeneity were analyzed to compare treatment plans.
For PTV59.4, the D, D, D, and V values in HT were significantly lower than other plans (all p < 0.05), and those in TD were significantly lower than VMAT and ff-IMRT (all p < 0.05). However, there was no significant difference in the D and D values between VMAT and ff-IMRT techniques (p > 0.05). The homogeneity index (HI) differed significantly for the 4 techniques of TD, HT, VMAT, and ff-IMRT (0.03 ± 0.01, 0.02 ± 0.01, 0.06 ± 0.02, and 0.05 ± 0.01, respectively; p < 0.001). The HI for TD was similar to HT (p = 0.166), and had statistically significant improvement compared to VMAT (p < 0.001) and ff-IMRT (p = 0.003). In comparison with the 4 conformity indices (CIs), there was no significant difference (p > 0.05). For PTV50.4, the D and D values in HT were significantly lower than other plans (all p < 0.05), and those in TD were significantly lower than VMAT and ff-IMRT (all p < 0.05). However, there was no significant difference in the D and D values between VMAT and ff-IMRT techniques (p > 0.05). No D and V parameters differed significantly among the 4 treatment types (p > 0.05). HT plans were provided for statistically significant improvement in HI (0.03 ± 0.01) compared to TD plans (0.05 ± 0.01, p = 0.003), VMAT (0.08 ± 0.03, p < 0.001), ff-IMRT (0.08 ± 0.01, p < 0.001). The HI revealed that TD was superior to VMAT and ff-IMRT (p < 0.05). The CI differed significantly for the 4 techniques of TD, HT, VMAT, and ff-IMRT (0.59 ± 0.10, 0.69 ± 0.11, 0.64 ± 0.09, and 0.64 ± 0.11, respectively; p = 0.035). The best CI was yielded by HT. We found no significant difference for the V, V, V, V, and the mean lung dose (MLD) among the 4 techniques (all p > 0.05). However, the V differed significantly among TD, HT, VMAT, and ff-IMRT (21.50 ± 7.20%, 19.50 ± 5.55%, 17.65 ± 5.45%, and 16.35 ± 5.70%, respectively; p = 0.047). Average V for the lungs was significantly improved by the TD plans compared to VMAT (p = 0.047), and ff-IMRT (p = 0.008). The V value of the lung in TD was 49.30 ± 13.01%, lower than other plans, but there was no significant difference (p > 0.05). The D of the spinal cord showed no significant difference among the 4 techniques (p = 0.056).
All techniques are able to provide a homogeneous and highly conformal dose distribution. The TD technique is a good option for treating upper thoracic EC involvement. It could achieve optimal low dose to the lungs and spinal cord with acceptable PTV coverage. HT is a good option as it could achieve quality dose conformality and uniformity, while TD generated superior conformality.
新型TomoDirect(TD)放疗模式提供了一种具有离散射束角度的非旋转选项。我们旨在比较TD、螺旋断层放疗(HT)、容积调强弧形放疗(VMAT)和固定野调强放疗(ff-IMRT)在上段食管癌(EC)中的剂量学参数。
纳入20例cT2-4N0-1M0上段食管鳞状细胞癌(ESCC)患者。为每位患者使用相同的剂量目标生成四个计划:TD、HT、单弧VMAT和5野(5F)ff-IMRT。规定剂量用于向计划靶区(PTV50.4)给予50.4 Gy/28F,然后向PTV59.4给予9 Gy/5F的追加剂量。分析剂量体积直方图(DVH)统计数据、剂量均匀性和剂量适形性以比较治疗计划。
对于PTV59.4,HT中的D、D、D和V值显著低于其他计划(均p < 0.05),TD中的这些值显著低于VMAT和ff-IMRT(均p < 0.05)。然而,VMAT和ff-IMRT技术之间的D和D值无显著差异(p > 0.05)。TD、HT、VMAT和ff-IMRT这4种技术的均匀性指数(HI)差异显著(分别为0.03±0.01、0.02±0.01、0.06±0.02和0.05±0.01;p < 0.001)。TD的HI与HT相似(p = 0.166),与VMAT(p < 0.001)和ff-IMRT(p = 0.003)相比有统计学显著改善。与4种适形指数(CI)相比,无显著差异(p > 0.05)。对于PTV50.4,HT中的D和D值显著低于其他计划(均p < 0.05),TD中的这些值显著低于VMAT和ff-IMRT(均p < 0.05)。然而,VMAT和ff-IMRT技术之间的D和D值无显著差异(p > 0.05)。4种治疗类型之间的D和V参数无显著差异(p > 0.05)。与TD计划(0.05±0.01,p = 0.003)、VMAT(0.08±0.03,p < 0.001)、ff-IMRT(0.08±0.01,p < 0.001)相比,HT计划在HI(0.03±0.01)方面有统计学显著改善。HI显示TD优于VMAT和ff-IMRT(p < 0.05)。TD、HT、VMAT和ff-IMRT这4种技术的CI差异显著(分别为0.59±0.10、0.69±0.11、0.64±0.09和0.64±0.11;p = 0.035)。HT的CI最佳。我们发现4种技术之间V、V、V、V和平均肺剂量(MLD)无显著差异(均p > 0.05)。然而,TD、HT、VMAT和ff-IMRT之间的V差异显著(分别为21.50±7.20%、19.50±5.55%、17.65±5.45%和16.35±5.70%;p = 0.047)。与VMAT(p = 0.047)和ff-IMRT(p = 0.008)相比,TD计划使肺部的平均V显著改善。TD中肺的V值为49.30±13.01%低于其他计划,但无显著差异(p > 0.05)。4种技术之间脊髓的D无显著差异(p = 0.056)。
所有技术都能够提供均匀且高度适形的剂量分布。TD技术是治疗上段EC受累的良好选择。它可以在可接受的PTV覆盖下实现对肺和脊髓的最佳低剂量。HT是一个好选择,因为它可以实现高质量的剂量适形性和均匀性,而TD产生了更好的适形性。